Brief: Incannex Healthcare Advances IHL-42X Reposa Trial To Phase 3 Following FDA Protocol Clearance
29/05/2025 12:36
May 29 (Reuters) - Incannex Healthcare Inc IXHL.O: INCANNEX HEALTHCARE INC. ADVANCES IHL-42X REPOSA TRIAL TO PHASE 3 FOLLOWING FDA PROTOCOL CLEARANCE INCANNEX HEALTHCARE INC - FDA AUTHORIZES INCANNEX'S PHASE 3 REPOSA CLINICAL TRIAL Source text: ID:nGNX822sGJ Further company coverage: IXHL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incannex Healthcare
See all newsIncannex Healthcare Inc reports results for the quarter ended June 30 - Earnings Summary
Incannex Healthcare Inc expected to post a loss of 75 cents a share - Earnings Preview
Brief: Incannex Receives Additional A$5.1 Million Research And Development Tax Incentive Refund
Brief: Incannex Healthcare Commences DReAMzz Clinical Study Of IHL-42X For Obstructive Sleep Apnea
Brief: Incannex Reactivates Share Repurchase Program, Underscoring Confidence In Valuation And Strategic Position